" class="no-js "lang="en-US"> ADARx Pharmaceuticals - Pharmtech Focus
Thursday, January 26, 2023

Breaking News

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Sharecare Launches VR Program to Improve Well-being of American Workforce Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Cerebral Therapeutics Names Julie Foster as Chief Operating Officer Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products Daewoong Pharmaceutical Submitted NDA for its Global New Drug Fexuclue in 11 Countries Roche launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-variant ProPharma Acquires UK Based Digital Lab Consulting
ADARx Pharmaceuticals | PTF

ADARx Pharmaceuticals

About ADARx Pharmaceuticals

ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.

Related Story

Fundraising

 ADARx Pharmaceuticals Raises $46 Million in Financing as Lead Product Enters the Clinic | PTF

ADARx Pharmaceuticals Raises $46 Million in Financing as Lead Product Enters the Clinic

January 23 2023

ADARx Pharmaceuticals, a clinical-stage biotechnology company developing RNA-targeting therapeutics, has announced the close of a […]